PHARMACY@UHB LIMITED

Financial Health Score: B (Stable, but requiring further internal examination)

Explanation: PHARMACY@UHB LIMITED presents a strong structural and regulatory profile, akin to a patient with a healthy heartbeat and excellent hygiene. The company has a long operating history, flawless filing compliance, and a robust governance framework. However, the quantitative financial vitals—such as cash flow, profitability, and asset base—are absent from this examination, preventing a perfect score. Additionally, the nominal £1 share capital and obscured People with Significant Control (PSC) suggest the company is a subsidiary reliant on a larger corporate "parent" for its financial lifeblood.

Key Vital Signs

• Pulse (Filing Compliance): Strong and steady. The company is fully up to date with both its annual accounts (made up to 31 March 2025) and confirmation statements. There are no overdue filings, indicating a healthy administrative heartbeat and no immediate signs of regulatory distress.
• Blood Pressure (Capital Structure): Dangerously low on paper, but likely normal for its condition. The company has a nominal share capital of just £1. While this might look like severe financial anemia, it is a common symptom of wholly-owned subsidiaries where the parent entity injects capital through director loans rather than share capital.
• Immune System (Corporate Governance): Highly robust. With seven directors and two secretaries, this patient has a very strong immune system. This large board is atypical for a small independent pharmacy and strongly suggests the company is closely governed by a larger NHS Trust or healthcare corporation.
• Medical History (Longevity & Rebranding): Healthy. Incorporated in 2011, the business has survived for over a decade. The recent name change in May 2024 (from PHARMACY@QEHB LIMITED) and an earlier change in 2011 (from SHOO 527 LIMITED) show the entity has adapted its identity, likely to align with the University Hospitals Birmingham (UHB) trust rebranding.
• Genetics (PSC & Ownership): Opaque. The PSC register only shows a "persons with significant control statement," meaning no individual is listed as owning over 25%. This confirms the "parent" diagnosis—a corporate entity (likely the NHS Trust itself) holds the reins, shielding the company from individual ownership risks.

Diagnosis

Symptoms Analysis: The financial data reveals a business that is structurally sound but deliberately kept on a tight financial leash. The £1 share capital means the business operates with virtually no equity buffer of its own. If this were a standalone independent pharmacy, this would be a critical symptom of distress—like a patient with no reserves to fight off an infection. However, given the hospital-based registered address (Queen Elizabeth Hospital Birmingham), the extensive board of directors, and the missing PSC, the diagnosis shifts. This is not a sick patient; this is a specialized appendage of a much larger organism.

The lack of individual PSCs and the presence of multiple directors who likely sit on the hospital trust's board indicate that PHARMACY@UHB LIMITED exists to provide specialized pharmacy and human health activities (SIC codes 47730 and 86900) strictly within the hospital's ecosystem. Its financial wellness is entirely intertwined with its parent; as long as the parent is healthy, this subsidiary will be supported.

Prognosis: The future outlook is stable and secure, heavily insulated by its relationship with the hospital trust. The company is not at risk of market volatility in the same way an independent high-street chemist would be. However, its long-term health is entirely dependent on the funding and strategic priorities of the wider NHS Trust. Any cuts or restructuring at the trust level could result in this entity being absorbed or dissolved, though this would be an administrative procedure rather than a financial insolvency.

Recommendations

1. Run the Full Blood Panel (Review Filed Accounts): While the regulatory pulse is strong, a true assessment of financial wellness requires examining the full filed accounts at Companies House. Stakeholders should review the balance sheet for director loans (which likely substitute for share capital) and the profit and loss reserve to ensure the company isn't accumulating silent losses.
2. Review Intercompany Liabilities: Given the £1 share capital, the company almost certainly relies on intercompany funding from its parent. It is vital to ensure these liabilities are structured favorably (e.g., not repayable on demand) to prevent a sudden cash flow crisis if the parent calls in the loan.
3. Update PSC Register: Although a corporate PSC statement is acceptable, ensuring the ultimate parent company is accurately recorded provides better transparency for stakeholders dealing with the pharmacy.
4. Monitor Contractual Health: The company's lifeblood is its relationship with the hospital. Regular reviews of the service or concession contract between the pharmacy and the trust are essential to ensure revenue streams remain uninterrupted.